The WalRK two-component system is essential for proper cell envelope biogenesis in

Clostridioides difficile

Ute Müh,[1] Craig D. Ellermeier[1], David S. Weiss[1]

[1]Department of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242

Corresponding authors: craig-ellermeier@uiowa.edu, david-weiss@uiowa.edu

Running title: WalRK is essential in *C. difficile*

Abstract (229 words)

The WalR-WalK two-component regulatory system (TCS) is found in all Firmicutes, where it regulates the expression of multiple genes required for remodeling the cell envelope during growth and division. Unlike most TCSs, WalRK is essential for viability, so it has attracted interest as a potential antibiotic target. Here we used overexpression of WalR and CRISPR interference to investigate the Wal system of *Clostridioides difficile*, a major cause of hospital-associated diarrhea in high-income countries. We confirmed the *wal* operon is essential and identified morphological defects and cell lysis as the major terminal phenotypes of altered *wal* expression. We also used RNA-seq to identify over 150 genes whose expression changes in response to WalR levels. This gene set is enriched in cell envelope genes and includes several predicted PG hydrolases and proteins that could regulate PG hydrolase activity. A distinct feature of the *C. difficile* cell envelope is the presence of an S-layer and we found WalR affects expression of several genes which encode S-layer proteins. An unexpected finding was that some Wal-associated phenotypic defects were inverted in comparison to what has been reported in other Firmicutes. For example, down-regulation of Wal signaling caused *C. difficile* cells to become longer rather than shorter, as in *Bacillus subtilis*. Likewise, down-regulation of Wal rendered *C. difficile* more sensitive to vancomycin, whereas reduced Wal activity is linked to increased vancomycin resistance in *Staphylococcus aureus*.

Importance (100 words)

The WalRK two-component system (TCS) is essential for coordinating synthesis and turnover of peptidoglycan in Firmicutes. Here we investigate the WalRK TCS in *Clostridioides difficile*, an important bacterial pathogen with an atypical cell envelope. We confirmed that WalRK is essential and regulates cell envelope biogenesis, although several of the phenotypic changes we observed were opposite to what has been reported in other Firmicutes. We also identified over 150 genes whose expression is controlled either directly or indirectly by WalR. Overall, our findings provide a foundation for future investigations of an important regulatory system and potential antibiotic target in *C. difficile*.

Introduction

To grow and divide, bacteria must thoroughly remodel their peptidoglycan (PG) sacculus, a large, covalently closed macromolecule that surrounds the cell and provides protection against rupture due to turgor pressure (1). How bacteria remodel the sacculus without making errors that lead to inadvertent lysis is a question that has fascinated microbiologists for decades. The question is also of practical significance because small molecules that undermine normal peptidoglycan biogenesis are among our most effective antibiotics.

An important advance in our understanding of cell envelope biogenesis was made over twenty years ago when Fabret and Hoch identified a *Bacillus subtilis* two-component system (TCS) that is essential for viability (2). This TCS is now called the Wal system and is known to coordinate expression of multiple cell envelope genes in the Firmicutes. WalRK is essential in all species studied so far, including pathogens such as *Staphylococcus aureus* (3-5) and *Streptococcus pneumoniae* (6, 7). Because of its essentiality, the Wal TCS has attracted interest as a potential antibiotic target.

The Wal TCS comprises the bifunctional kinase/phosphatase WalK together with its cognate response regulator WalR. In addition, *wal* operons typically include genes for membrane proteins known or presumed to modulate WalK activity, but the accessory proteins differ between organisms (8-10). Recent evidence from *B. subtilis* indicates WalK activity is regulated by PG fragments generated by PG hydrolases that open spaces to make room for elongation. These PG fragments bind to WalK's extracellular Cache domain to modulate the phosphorylation state of WalR (11). Phosphorylated WalR in turn binds to various promoters to activate or repress gene expression.

The number of genes in the WalR regulon ranges from about a dozen to over 100 (5, 12-16), depending on the species, and only some of these genes are directly activated or repressed by WalR. Although WalR regulons are diverse, they invariably include multiple proteins that contribute to proper biogenesis of the cell envelope, especially PG hydrolases. Consistent with these themes, the phenotypic

defects elicited by artificial up- or down-regulation of WalRK signaling include abnormal cell shape, larger

cells, smaller cells, ghost cells (lysis), thicker PG, abnormal division septa and altered sensitivity to

antibiotics that target PG biogenesis (8-10). In *S. pneumoniae walRK* is essential because it activates

expression of an essential PG hydrolase, *pcsB* (6, 7). However, the essentiality of *walRK* in *B. subtilis*

and *S. aureus* is polygenic in nature, resulting from abnormal expression of multiple genes that are not

by themselves essential. In all three organisms, it is possible to bypass the *walRK* requirement by

constitutively expressing one or more Wal regulon PG hydrolases, sometimes in combination with

deleting genes for hydrolase inhibitors (6, 17, 18).

Here we studied the WalRK TCS in *Clostridioides difficile*, an anaerobic, spore-forming Firmicute

responsible for close to a quarter million hospitalizations and over 12,000 deaths per year in the United

States (19). Unlike the envelope of most Firmicutes in which *walRK* has been studied previously, the *C.*

difficile envelope has a proteinaceous S-layer whose assembly presumably must be coordinated with PG

synthesis (20-22). In addition, the PG itself is somewhat unusual (23). About 90% of the *N*-

acetylglucosamine is deacetylated (which has implications for PG hydrolase activity) and about 70% of

the peptide crosslinks are 3-3 rather than 4-3 (which has implications for the structure of PG fragments

thought to bind to the Cache domain of WalK (11)). The *C. difficile* Wal system includes a unique

lipoprotein gene and a non-canonical WalK that lacks an intracellular PER-ARNT-SIM (PAS) signaling

domain (Fig. 1) (10). These features distinguish *C. difficile's* WalRK TCS from those of previously

characterized Firmicutes, although a distantly related *wal*-like system in *Mycobacterium tuberculosis*

(MtrAB) includes a lipoprotein and a WalK-like histidine kinase without an intracellular PAS domain (10,

24, 25). Finally, our recent development of tools for xylose-inducible gene expression and CRISPR

interference (26) helped to overcome some of the challenges inherent in phenotypic analysis of essential

genes like *walRK* in *C. difficile*.

Results

The *wal* operon is required for cell viability, proper rod morphology and intrinsic resistance to some antibiotics. According to Tn-seq, the WalRK TCS is essential in *C. difficile* (27). To confirm and extend this finding, we leveraged the power of CRISPR interference (CRISPRi) for functional analysis of essential genes/operons (28). Our CRISPRi system comprises a xylose-inducible nuclease-defective Cas9, P$_{xyl}$::*dCas9*, that is targeted to a gene of interest by a single guide RNA expressed constitutively from the glutamate dehydrogenase promoter, P$_{gdh}$::*sgRNA* (26). Because CRISPRi is polar, we decided to target the first gene in the operon, which encodes a predicted lipoprotein unique to the *C. difficile wal* operon (Fig. 1). We have named this gene *walA.* For reproducibility, we designed two guides against *walA*, sgRNA-*walA1* and sgRNA-*walA2*. Subsequent RNA-seq experiments described below confirmed that targeting dCas9 to *walA* suppressed transcription of the entire operon. As a negative control we used a sgRNA (sgRNA-neg) that does not have a target anywhere on the *C. difficile* chromosome. In some experiments the CRISPRi machinery was produced from a plasmid that confers resistance to thiamphenicol (Thi), while in others it was integrated into the chromosome at the *pyrE* locus in a way that does not leave behind an antibiotic resistance marker (29).

Chromosomal- or plasmid-based CRISPRi knockdown of the *wal* operon in either 630Δerm or R20291 reduced viability ≥10^4-fold when cell were plated on TY-agar containing 1% xylose (Fig. 2A and Fig. S1A). Additional phenotypes were characterized in TY broth using 630Δerm derivatives with the CRISPRi machinery integrated at *pyrE*. In the absence of xylose, sgRNA-*walA1* and sgRNA-*walA2* retarded growth slightly compared to the sgRNA-neg control (Fig. 2B, S1B). This finding indicates there is leaky expression of P$_{xyl}$::*dCas9,* which was later confirmed by RNA-seq (see below). Under these conditions, cells were on average about 10% longer than wild-type and the fraction of cells with curved or irregular contours increased from ~1% in the sgRNA-neg control to ~20% for sgRNA-*walA1* or ~10% for sgRNA-*walA2* (Fig. 2C-E, S1E,F). Further knockdown of the *wal* operon by addition of xylose exacerbated the growth defect in a dose-dependent manner (Fig. 2B, S1D). In addition, morphological

defects became more pronounced, with cells now averaging ~30% longer than controls and up to ~40%

exhibiting curved or irregular contours (Fig. 2D,E and S1E,F).

Partial knockdown of the *wal* operon in the absence of xylose allowed us to screen for altered

sensitivity to antibiotics that target cell envelope biogenesis. We found that the minimal inhibitory

concentration (MIC) for ampicillin and daptomycin decreased about 2-fold, while the MIC for vancomycin

decreased about 4-fold (Table 1). But sensitivity to the other two cell wall-active antibiotics, imipenem

and bacitracin, or the gyrase inhibitor novobiocin was not affected (Table 1).

Overexpression of WalR impairs growth, alters morphology and slows autolysis. We also

investigated Wal function in *C. difficile* by overproducing the response regulator WalR to drive cells into

an exacerbated Wal-ON state (5, 30). Plating *C. difficile* 630Δerm harboring a P_{xyl}::*walR* expression

plasmid onto TY-Thi containing 1% xylose resulted in a 10^6-fold loss of viability (Fig. 3A). This strain failed

to grow when subcultured directly into TY-Thi broth containing 1% xylose, but waiting until OD_{600} ~0.2

before adding 3% xylose resulted in only a subtle growth defect (Fig. 3B). Three hours post-induction,

the cells had become strikingly phase bright and resistant to autolysis when suspended in buffer

containing 0.01% Triton X-100 (Fig. 3C,D). Triton X-100 is thought to reduce the inhibitory effect of

lipoteichoic acids on PG hydrolases (31, 32). Similar results were obtained in the R20291 strain

background (Fig. S3). It is unclear what causes cells to turn phase bright upon overexpression of *walR*.

Differential staining with Syto 9 and propidium iodide (LIVE/DEAD staining) indicates that >99% of the

cells are alive after overproduction of WalR (Fig. 3B, red arrow).

We repeated these experiments after integrating P_{xyl}::*walR* into the chromosome of 630Δerm. As

expected, the effects of xylose induction were similar but less pronounced when P_{xyl}::*walR* was in single

copy (Fig. 4A). The addition of xylose at subculture was now tolerated and reduced growth in a dose-

dependent manner. At 3% xylose, cells became slightly phase-bright. There were some bent or hooked

cells, a defect not observed with the P_{xyl}::*walR* plasmid, perhaps because it could only be induced for

shorter times. (Fig. 4C). After 6h of induction, cells were harvested and evaluated in the lysis assay. We

found that overexpression of *walR* slowed lysis in a dose-dependent manner (Fig. 4B).

Expression profiling under Wal-ON conditions. As a step towards understanding the basis of the

various Wal-related phenotypes, we sought to identify the genes in the *wal* regulon. (Note: we use the

term regulon for convenience to refer to genes whose expression responds to manipulation of the *wal*

operon regardless of whether these effects are direct or indirect.) We began by performing RNA-seq on

two strains that overexpress *walR* from a single copy P_{xyl}::*walR* construct integrated at *pyrE*. One of these

strains overproduced wild-type WalR, the other overproduced a WalR[D54E] mutant protein expected to

mimic phosphorylated WalR and thus be constitutively active (13, 33) (Confusingly, D54 is annotated as

D66 in the R20291 genome on the BioCyc website). The two strains behaved similarly with respect to

growth and performance in the lysis assay (Fig. S4A,B). The control strain for these experiments had the

gene for a red fluorescent protein (*rfp*) integrated at *pyrE* (26). Strains were grown overnight in TY, then

subcultured into fresh TY at a starting OD_{600} ~0.05. When the OD_{600} reached ~0.2, cultures were induced

with 3% xylose and allowed to grow for three hours (~ 2 mass doublings), at which time cells were

harvested and processed for RNA-seq. At this time point induction of *walR* had only a small effect on

growth rate (Fig. S4A) and >99% were viable as judged by LIVE/DEAD staining.

Not including *walR*, which was induced directly from P_{xyl}, the RNA-seq analysis identified 77

genes whose transcript abundance changed ≥4-fold (p<0.05) upon overexpression of either *walR* or

walR[D54E] (Table 2). Of these genes, 44 were induced and 33 were repressed. Induction ratios were very

similar in the *walR* and *walR*[D54E] strains with only two exceptions, *cd630_03901* and *cd630_10631*, both

of which encode hypothetical proteins. The failure of the D54E substitution to increase gene expression

could mean it is not activating in *C. difficile* WalR, as reported previously for some other response

regulators (34). Alternatively, overexpression of *walR* is itself activating and might obscure the effects of

the substitution. The 77 genes are predicted by BioCyc (35) to be organized into 65 operons that contain

18 additional genes which missed our 4-fold expression change cut-off. Visual inspection of the

expression data revealed these genes almost always trended in the right direction, confirming the

predicted structure of most of the operons. We therefore included these 18 genes in what we will refer to

as the Wal-ON regulon, bringing it to a total of 95 genes in 65 operons (Table 2).

Several of the genes and trends in Table 2 are worth highlighting. Xylose induction resulted in a

14-fold increase in *walR* mRNA (13-fold for *walR*[D54E]), while the levels of *walK* or other members of the

native operon were not affected. This means that induction of P$_{xyl}$::*walR* integrated at *pyrE* does not lead

to induction of the native *wal* operon, consistent with reports that the *wal* operon is not auto-regulated in

other bacteria (8, 16). Another striking feature of Table 2 is the abundance of genes encoding for cell

envelope proteins. Of the 95 genes in Table 2, 22 (23%) are predicted to encode exported proteins and

29 (31%) are predicted to encode cytoplasmic membrane proteins. For comparison, ~7% of the entire

proteome is predicted to be exported and 23% predicted to be membrane proteins (see Methods). Table

2 also includes 21 hypotheticals (22% of the total), many of which are likely to be involved in cell envelope

processes based on the presence of predicted transmembrane domains or export signals.

Peptidoglycan-associated genes, especially PG hydrolases, are prominent members of the Wal

regulon in all Firmicutes examined to date (8, 10), and *C. difficile* is no exception. Table 2 lists ten

peptidoglycan-associated genes, including the second most highly induced gene, *pgdA*, which was

upregulated 16-fold. PgdA deacetylates N-acetylglucosamine in peptidoglycan, and is important for *C.*

difficile's high lysozyme resistance (36, 37). AsnB (~8-fold induced) is annotated as an asparagine

synthetase, but its primary function is to amidate diaminopimelic acid in PG stem peptides (38). In *B.*

subtilis, amidation of m-DAP inhibits PG hydrolase activity (39). MurE (7-fold repressed) catalyzes one

of the cytoplasmic steps in PG synthesis, addition of diaminopimelic acid to the nucleotide-linked PG

precursor (40). Down regulation of *murE* suggests PG synthesis may be decreased in Wal-ON conditions.

Cwp16 and Cwp17 are S-layer proteins with predicted amidase domains (41) and were upregulated

about 4-fold. Cell wall amidases cleave the amide bond that links stem peptides to N-acetylglucosamine

in PG glycan strands (42). CD630_36010 (4-fold induced) is a predicted D-alanyl-D-alanine

carboxypeptidase that removes the terminal D-Ala moiety from peptidoglycan pentapeptide sidechains.

This might limit 4-3 crosslinking of stem peptides, but could favor 3-3 crosslinking. Two proteins of

unknown function were upregulated >10-fold, CD630_07390 and CD630_07380. We suspect both of

these proteins are involved in PG metabolism because they are predicted to be exported and also

induced by lysozyme (43). Notable among the repressed genes in Wal-ON cells is *cd630_27680*, which

is down regulated about 4-fold and predicted to encode a cell wall hydrolase from the NlpC/P60 family,

a domain common to endopeptidases (42). Interestingly, this gene is preceded by two putative WalR

binding sites, and it has also been characterized as a sortase substrate (44). Another predicted PG

hydrolase, CD630_23880, is mildly repressed (~3-fold). Interestingly, this gene is cotranscribed with an

uncharacterized BlaI-BlaR regulatory system, *cd630_23890* and *cd630_23900*. Some BlaIR regulatory

systems respond to beta-lactam stress (45, 46).

One of the questions that motivated this study was whether the WalR system regulates genes for

S-layer proteins in *C. difficile*. Indeed, the Wal-ON regulon includes six S-layer protein genes, all of which

are upregulated by WalR: *cwp2*, *5*, *12*, *16*, *17* and *66*. Two of these genes were mentioned already, the

cell wall amidases *cwp16* and *cwp17*. The remaining four are of unknown function, although *cwp2* and

cwp12 have domains implicated in adhesion or pathogenesis, and studies with *cwp66* have linked it to

adhesion, autolysis and resistance to antibiotics (41, 47). WalRK has been suggested to regulate an S-

layer gene in *Bacillus anthracis* (48).

Expression profiling under Wal-OFF conditions. As a complementary approach to identify genes in

the WalR regulon, we assessed the effect of CRISPRi knockdown of the *wal* operon on global gene

expression. To this end, we performed RNA-seq on a 630Δerm derivative that has the CRISPRi

machinery (P_{xyl}::*dCas9*, P_{gdh}::*sgRNA-walA1*) integrated into the chromosome at *pyrE*. The control strain

was identical except that it expressed an innocuous sgRNA that does not target anywhere in the *C.*

difficile genome (P_{gdh}::*sgRNA*-neg). Two induction conditions were used. One of these, called "no xylose",

relied on leaky expression of *dCas9*. For this, overnight cultures were diluted into fresh TY to a starting

OD_{600} = 0.03 and harvested when they reached OD_{600} ~0.7 (Fig. S4C). For the other condition, called

"low xylose", cultures in exponential growth where induced with 0.1% xylose at an OD_{600} = 0.1 and

incubated 2.5 hours (~2 mass doublings) before harvest. This induction regimen reduced cell density

only modestly (Fig. S4D).

There are 49 genes, organized in 27 operons that shift 4-fold or more under Wal-OFF conditions

(Table 3). The 27 operons contain an additional 14 genes that did not meet our 4-fold cut-off, all but three

of which nevertheless trended in the right direction. The three exceptions include a pseudogene

(*cd630_05260*) that is not detected by our RNA-seq analysis tool and two membrane proteins

(*cd630_05290* and *05280*) whose expression was unchanged. Thus, for the purposes of this analysis,

CRISPRi knockdown of the *wal* operon changed the expression of 60 genes, of which 44 were induced

and 16 were repressed. Curiously, for most of these genes the fold-change was larger in the absence of

xylose, suggesting that many of the effects on gene expression might be indirect.

The CRISPRi guide targets the first gene in the operon, *walA*, which was repressed 6.8-fold in

the absence of xylose and 35-fold with low xylose. As expected, polarity resulted in repression of the

downstream genes as well, ~5-fold with leaky CRISPRi, increasing to ~15-fold with low xylose. The

observed polarity confirms the predicted operon structure, including that a seemingly unrelated (and

according to Tn-seq nonessential) gene for a tRNA modification enzyme is indeed part of the operon.

Unexpectedly, the Wal-OFF gene set comprises mostly transporters and genes for various

metabolic functions. Not counting the members of the *wal* operon, only one of the genes is predicted to

be exported and 15 genes (25%) to be membrane proteins, a percentage comparable to the genome as

a whole (Methods). Remarkably, the Wal-OFF regulon does not include a single annotated PG

metabolism gene. However, we observed ~5-fold repression of the *dltDABC* operon, which is responsible

for the addition of D-alanine to teichoic acids (49). We identified a predicted WalR binding site

immediately upstream of *dltDABC*, suggesting direct regulation by WalR. This putative WalR binding site

had previously been recognized as one of two direct repeat sequences in the *dlt* promoter region ((49),

Table S4). D-alanylation of teichoic acids affects PG hydrolase activity (50, 51) and vancomycin

resistance in some bacteria (52, 53). In *C. difficile*, a *dltD* insertion mutant is sensitized to vancomycin

and some antimicrobial peptides, but the effects are <2-fold (52). Only one gene in Table 3 codes for an

S-layer protein—the hemagglutinin/adhesin *cwpV*, which was ~16-fold induced in no xylose. But this

gene is subject to phase variation (54), leading us to suspect it may not be a true member of the WalR

regulon.

Comparison of the Wal-ON and the Wal-OFF gene sets reveals little overlap but opposing trends.

There are only two proteins common to the Wal-ON and the Wal-OFF gene sets, *cd630_20160*

(hypothetical protein) and *cd630_28620* (annotated as a membrane peptidase). However, a large fraction

of the 79 Wal-ON genes that met the 4-fold cut-off trend in the opposite direction when evaluated under

Wal-OFF conditions, even though the magnitude of change is not as large (Fig. 5A, Table 2). A similar

observation was made when genes affected 4-fold or more under Wal-OFF conditions were examined

under Wal-ON conditions (Fig. 5B, Table 3).

Select members of the WalR regulon were confirmed by plasmid-based reporter fusions. To

confirm results of the RNA-seq analysis, we constructed *rfp* transcriptional fusions (55) to the promoter

regions for seven genes from the Wal-ON or Wal-OFF gene sets. Four genes were chosen primarily

because they were highly-induced when WalR was overexpressed: *cd630_07390*, *pgdA*, *cd630_07380*,

and *cd630_08670* (Table 2). Additional considerations included that *pgdA* has an obvious connection to

PG biogenesis (36, 37), while *cd630_08670* has a predicted WalR-binding site (Table S4). Two genes

were chosen because they were the most strongly repressed upon CRISPRi knockdown of the *wal*

operon and are preceded by a predicted WalR-binding site: *cd630_28620* and *cd630_05300* (Tables 3,

S4). In addition, *cd630_28620* is one of only two genes that made the 4-fold cut-off in both Wal-ON and

Wal-OFF conditions. The final gene chosen for confirmation with an *rfp* reporter was *dltD*, which

incorporates D-alanine into teichoic acids (49) and was modestly downregulated by CRISPRi knockdown

of the *wal* operon. *dltD* stood out because it has a predicted WalR-binding site and is one of the few cell

envelope-associated genes that was at least 4-fold repressed in Wal-OFF conditions (Tables 3, S4).

Reporter plasmids were constructed by PCR-amplifying ~300 bp upstream of the start codon for

each selected gene. These fragments contain transcriptional start sites for five of the seven genes (Clost-

Base database (56)); start sites for the remaining two genes have not been mapped. The PCR products

were cloned into an RFP reporter plasmid. The resulting plasmids were conjugated into the appropriate

Wal-ON and Wal-OFF strain pairs: 630Δerm versus 630Δerm P$_{xyl}$::*walR* and 630Δerm with sgRNA-*walA1*

versus 630Δerm sgRNA-neg, respectively. Reporter strains were grown under the same conditions as

used for the RNA-seq experiments, except that the Wal-OFF condition was limited to growth in the

absence of xylose, i.e., assaying the effect of leaky dCas9 expression on the reporter gene. Harvested

cells were fixed and transferred to aerobic conditions to allow RFP to mature. Fluorescence was

quantified by flow cytometry.

We found that all RFP reporters responded in the expected direction when *walR* expression was

manipulated, thus confirming the RNA-seq results by an orthogonal method (Fig. 6). However, the fold

changes were uniformly about 4-fold greater by RNA-seq than by RFP fluorescence. The reasons for this

difference are not known. As an aside, having RNA-seq and RFP fluorescence data for the same genes

enabled us to show these are correlated, i.e., baseline RFP fluorescence was higher for genes that

returned more reads in RNA-seq experiments (Fig. S5A). This correlation was expected and further

indicates our RNA-seq data are robust.

Altering the expression level of select regulon genes does not induce the *wal* reporter. In *B.*

subtilis, the WalR regulon can be induced or repressed by manipulating expression of *walR*-regulated

genes involved in PG metabolism (11, 57). We therefore asked whether manipulating expression of *wal*

regulon genes in *C. difficile* would induce or repress expression of a chromosomal P$_{cd630\_07390}$::*rfp*

reporter. The reporter was chosen because this promoter was highly induced in Wal-ON conditions as

determined by RNA-seq (38-fold) or a plasmid-based RFP reporter fusion (7-fold). The chromosomal

P$_{cd630\_07390}$::*rfp* reporter was validated by confirming ~10-fold increased red fluorescence upon

overexpression of *walR* from a P$_{xyl}$ plasmid (Fig. S5B). Next, we introduced a panel of plasmids that

allowed us to directly target 13 WalR regulon genes by overexpression and/or CRISPRi. These 13 genes

were chosen for various reasons including large fold-changes in expression, relevance to cell wall

biogenesis, and the presence of WalR binding sites (Table S3). Of note, the gene set included a putative

cell wall amidase and the predicted PG hydrolase with a NlpC/P60 domain. Unfortunately, neither

overexpression nor CRISPRi knockdown of the selected *wal* regulon genes altered expression of the

P*cd630_07390*::*rfp* reporter. Further work will be needed to determine whether these negative results reflect

technical difficulties or more fundamental differences in Wal signaling between *B. subtilis* and *C. difficile*.

Perturbation of select Wal regulon genes individually does not lead to any Wal-associated

phenotypic defects. As noted above, one motivation for determining the Wal regulon was to identify

genes that contribute to Wal phenotypes. Recall that induction of P$_{xyl}$::*walR* decreases viability, causes

cells to become phase bright and reduces autolysis in buffer containing 0.01% Triton X-100 (Fig. 3). Two

of the most highly induced genes in Wal-ON conditions encode the hypothetical proteins CD630_07380

and CD630_07390. However, overproduction of these proteins either individually or from P$_{xyl}$ plasmids

did not result in any obvious phenotypic changes (Fig. 7). Note, because these genes are transcribed

divergently (35), we needed to reverse the direction of one gene to express them together and decided

to clone both possible arrangements: *cd630_07380-cd630_07390* and *cd630_07390-cd630_07380*.

Likewise, a CRISPRi plasmid with an sgRNA that targets *cd630_27680* had no effects on growth,

morphology or lysis (Fig. 7); this gene encodes PG hydrolase with two predicted WalR-binding sites and

is among the most strongly repressed genes in Wal-ON conditions.

CRISPRi silencing of the *wal* operon is lethal, and the terminal phenotypes include lysis and loss

of rod shape as reflected by an abundance of curved cells (Fig. 2). However, none of these phenotypes

were observed when we used a P$_{xyl}$::*cwpV* plasmid to overexpress the most highly-induced gene from

the Wal-OFF RNA-seq data set, which we tested even though *cwpV* is subject to phase-variation and

might not be part of the WalR regulon. We also observed an effect when we used CRISPRi to knock

down expression of *dltD*, which was among the more strongly repressed Wal-OFF genes and is preceded

by a putative WalR binding site (Fig. 8). While not an exhaustive evaluation of all regulon members, our

findings suggest the phenotypic defects observed upon perturbation of the Wal system are not due to

changes in expression of any single gene, but cumulative in nature much like what has been observed

in *B. subtilis* and *S. aureus* (8-10, 12).

Discussion

In *C. difficile* the WalRK TCS is predicted to reside in a four gene operon: *walA-walR-walK-truA2*.

We altered expression of the WalRK regulon by complementary approaches: depleting *C. difficile* of

WalRK by CRISPRi knockdown of the entire operon, and overproduction of WalR under P_{xyl} control. RNA-

seq revealed the *wal* operon is not autoregulated in *C. difficile*, as evidenced by a lack of induction when

WalR (or WalR^{D54E}) was ectopically expressed from a P_{xyl} promoter. Wal operons are not autoregulated

in other Firmicutes either. RNA-seq also confirmed the genes constitute an operon, because CRISPRi

targeting *walA* resulted in roughly equivalent knockdown of the three downstream genes. Further studies

will be needed to establish the specific role of each gene in WalRK signaling. We suspect *walA* is a bona

fide part of the Wal system because all *wal* operons studied to date include accessory genes for

membrane proteins that modulate WalK signaling (8, 10). But a rationale for why a non-essential tRNA

modification enzyme, *truA2,* should have come to reside in the *wal* operon is not obvious. This might be

the result of evolutionary happenstance.

As expected, extensive knockdown of the *wal* operon with CRISPRi or strong overproduction of

WalR from a P_{xyl} plasmid were both lethal. Phenotypic defects depended on how *walRK* expression was

manipulated, but included elongation, loss of rod shape (curved or wavy cells), phase bright cells,

enhanced or reduced autolysis, and altered sensitivity to antibiotics that target PG synthesis. Similar

phenotypes have been observed upon manipulating Wal signaling in other organisms (2, 6, 7, 9, 10, 12,

17, 18). But there are some intriguing differences. In *B. subtilis*, where phosphorylated WalR promotes

elongation, artificial upregulation of the Wal system causes cells to become elongated while artificial

downregulation causes cells to become short (10, 18). In *C. difficile*, however, overexpression of WalR

from P*xyl* had no obvious effect on cell length while CRISPRi knockdown of the *wal* operon led to

elongation.

Vancomycin resistance presents another example of an inverse phenotype. In *S. aureus* down

regulating *walRK* expression increases resistance to vancomycin while up regulation of *walRK* decreases

vancomycin resistance (58, 59). Vancomycin-intermediate *S. aureus* (VISA) strains, both laboratory

derived (60) or isolated in the clinic (61), often have mutations in *walR* or *walK* that down regulate the

system (62). In contrast, we found that partial CRISPRi knockdown of the *wal* operon in *C. difficile* had

the opposite effect, namely, a modest increase in sensitivity to vancomycin. Vancomycin is a front line

treatment for *C. difficile* infections, so our findings suggest a small molecule that interferes with Wal

signaling might enhance the efficacy of vancomycin therapy.

RNA-seq identified over 150 genes whose expression responds to manipulation of Wal signaling

in *C. difficile*. Although this gene set is diverse, there are themes: many cell envelope proteins, many

hypotheticals, and about 10 proteins with various connections to PG metabolism. There are also 7 genes

for S-layer proteins, consistent with the need to coordinate S-layer assembly and remodeling with growth

and turnover of the PG sacculus. The PG hydrolases are of particular interest because they are prominent

members of the WalR regulon in other Firmicutes (5, 12-16) and ectopic expression of one or more of

these enzymes can render *walRK* no longer essential regulators (6, 17, 18). In *C. difficile*, Wal-ON

conditions induced two putative cell wall amidases (*cwp16*, *cwp17*) and repressed one potential D,L-

endopeptidase (*cd630_27680*). Direct control of *cd630_27680* by WalR is suggested by the presence of

two matches to the WalR binding site consensus sequence about 100 nucleotides upstream of the start

codon (Table S4). The importance of these genes for any Wal-related phenotypes is unclear, however,

because overexpression and CRISPRi knockdown experiments did not result in any phenotypic changes

or alter expression of an RFP reporter that is induced under Wal-ON conditions. In addition to the putative

hydrolases, several genes in the WalR regulon may play a role in *controlling* PG hydrolase activity.

Deacetylation of PG N-acetylglucosamine (GlcNAc) (63), mDAP amidation (39), and D-alanylation of

teichoic acids (32, 50, 51, 64) have all been shown to affect hydrolase activity in other organisms.

S. pneumoniae is so far the only organism in which a single essential gene, the PG hydrolase

pcsB, has been identified to be responsible for the essentiality of the *wal* system (6, 7). In *B. subtilis*,

essentiality of the Wal system arises from the cumulative impact of aberrant expression of multiple genes

involved in turnover of PG (5, 10, 11). Wal essentiality is also polygenic in nature in *S. aureus* (8). This

seems to be the case in *C. difficile* as well. Although CRISPRi silencing of the *wal* operon leads to cell

lysis, the Wal-OFF gene set (Table 3) does not include any genes determined to be essential by

transposon mutagenesis (27). In contrast, the Wal-ON regulon (Table 2) includes 3 essential genes. Two

of these are induced by WalR, DNA ligase (*ligA, cd630_33090*) and a putative Calcium-chelating protein

(*cd630_26810*); one is repressed, the PG precursor synthesis protein MurE (*cd630_26640*). It is possible

that repression of *murE* contributes to death during overexpression of WalR, but not during CRISPRi

knockdown of the *wal* operon, because *murE* expression did not change under that condition. Overall,

our findings suggest essentiality of WalRK is driven by a deleterious imbalance of multiple processes.

(As an aside, it is worth noting that repression of *murE* under Wal-ON conditions is not what one would

expect if WalR promotes increased PG synthesis, as in *B. subtilis* (11, 57)).

Here we have provided an initial delineation of Wal phenotypes and the WalR regulon in *C.

difficile*. Our findings raise a number of exciting questions. Is the protein WalA involved in WalRK

signaling, and if so, how? What signals are sensed by WalK? Of note, owing to differences in crosslinking

(23), the PG hydrolysis products implicated in regulating WalK activity in *B. subtilis* (11) are not very

abundant in *C. difficile*. Moreover, *C. difficile* WalK is missing an intracellular PAS domain found in most

other WalK proteins, suggesting *C. difficile* WalK senses different signals and/or transmits those signals

differently. Another open question is which WalR regulon genes are controlled directly by WalR. It will

also be important to determine the functions of the WalR regulated genes, especially the many

hypothetical proteins. Answers to these questions are likely to provide novel insights into cell wall

biogenesis and might point the way towards improved therapies against this important pathogen.

Methods

Strains, media, and growth conditions. Bacterial strains are listed in Table 4. *C. difficile* strains used

in this study were derived from either 630Δerm or R20291, both of which have been sequenced. *C.*

difficile was routinely grown in tryptone-yeast extract (TY) medium, supplemented as needed with

thiamphenicol at 10 µg/ml (TY-Thi). TY medium consisted of 3% tryptone, 2% yeast extract, and 2% agar

(for plates). Brian heart infusion (BHI) media was prepared per manufacturer's (DIFCO) instructions. *C.*

difficile strains were maintained at 37°C in an anaerobic chamber (Coy Laboratory Products) in an

atmosphere of 10% H_2, 5% CO_2, and 85% N_2. *Escherichia coli* strains were grown in LB medium at 37°C

with chloramphenicol at 10 µg/ml or ampicillin at 100 µg/ml as needed. LB medium contained 1%

tryptone, 0.5% yeast extract, 0.5% NaCl, and 1.5% agar (for plates). OD_{600} measurements were made

with the WPA Biowave CO8000 tube reader in the anaerobic chamber.

Plasmid and strain construction. All plasmids are listed in Table 5; an expanded version of this table

which includes additional information relevant to plasmid assembly is provided in Table S2A in the

supplemental material. Plasmids were constructed by isothermal assembly (65) using reagents from New

England Biolabs (Ipswich, MA). Regions of plasmids constructed using PCR were verified by DNA

sequencing. The oligonucleotide primers used in this work were synthesized by Integrated DNA

Technologies (Coralville, IA) and are listed in Table S2B. All plasmids were propagated using OmniMax

2-T1R as the cloning host, transformed into HB101/pRK24 (66, 67), and then introduced into *C. difficile*

strains by conjugation. Chromosomal fusions at the *pyrE* locus in 630Δerm were constructed by allelic

exchange (29) using *C. difficile* CRG1496 (630Δ*erm* Δ*pyrE*) as a *pyrE*-deficient recipient. The allelic

exchange restored a functional *pyrE* gene.

Conjugation into *C. difficile.* Our experiments required conjugating plasmids into *C. difficile* strains R20291 and 630Δerm. In the case of R20291 we encountered problems with low conjugation efficiencies even with heat shock as described (68). After testing several modifications of the procedure, we found that performing conjugations on filters reliably increased efficiency more than 10-fold (Fig. S6). We now routinely use filters for all our conjugations. Briefly, the *E. coli* donor strain (an HB101/pRK24 derivative harboring the cargo plasmid) was grown overnight in LB Amp[100] Cam[10]. The donor strain was collected gently by centrifugation of a 0.5 ml aliquot at 5000 x g for 1 min, then washed with 1 ml TY and pelleted again. The washed cell pellet was moved into the anaerobic chamber. R20291 was prepared for conjugation by a heat shock step (68). For this, a 200 µl aliquot of the overnight culture of the R20291 recipient was transferred to a 1.5 ml microfuge tube and incubated at 48°C for 5 min in a Fisherbrand Dry bath (with water-filled wells). Then 100 µl of heat-shocked R20291 was used to take up the pellet of *E. coli* donor cells. The strain mixture was then pipetted on to a 25 mm diameter, 0.45 µm pore size Millipore mixed cellulose filter (HAWP02500) placed on brain heart infusion (BHI) plates. After incubation for 24 h at 37°C, cells were flushed from the membrane with 500 µL TY and 200-500 µL of the resulting bacterial slurry was plated on TY amended with thiamphenicol (10 µg/ml), kanamycin (50 µg/ml) and cefoxitin (8 µg/ml) to select for exconjugants. Conjugations into 630Δerm were done identically except the heat shock step was omitted.

Viability assay. The effect of CRISPRi silencing on plating efficiency was evaluated by making a 10-fold serial dilution of a culture grown overnight in TY Thi10 and spotting 5 µl of each dilution on TY Thi10 agar with and without 1% xylose. Plates were photographed after overnight incubation (~18 h).

Microscopy. Cells were immobilized using thin agarose pads (1%). Phase-contrast and fluorescent micrographs were recorded on an Olympus BX60 microscope equipped with a 100× UPlanApo objective (numerical aperture, 1.35). Micrographs were captured with a Hamamatsu Orca Flash 4.0 V2+

complementary metal oxide semiconductor (CMOS) camera. The image analysis tool MicrobeJ (69) was

used to measure cell length and sinuosity, which is the length of the cell axis divided by the distance

between the poles. A perfectly straight rod has a sinuosity value of 1, while a curved or wavy cell has a

larger value. We classified cells as curved if their sinuosity was ≥1.03 (see Fig. S2 for examples). Viability

of cells was assessed with LIVE/DEAD stain (Molecular Probes L7012). A 1 mL culture sample was

pelleted, washed with PBS and resuspended in 100 µL PBS with 5 µM Syto 9 and 30 µM propidium

iodide. Cells were incubated with the dyes for 15 min, then removed from the anaerobic chamber and

immediately imaged by microscopy. For propidium iodide red fluorescence we used filter set 41004

(Chroma Technology) with a 538 to 582-nm excitation filter, 595-nm dichroic mirror (long pass), and a

582 to 682-nm emission filter. Syto 9 green fluorescence was captured with filter set 41017 (Chroma

Technology Corp) with a 450- to 490-nm excitation filter, a 495-nm dichroic mirror (long pass), and a 500-

to 550-nm emission filter.

Fixation protocol. A 500-µl aliquot of cells in growth medium was added directly to a microcentrifuge

tube containing 120 µl of a 5x fixation cocktail: 100 µl of a 16% (wt/vol) paraformaldehyde aqueous

solution (Alfa Aesar, Ward Hill, MA) and 20 µl of 1 M $NaPO_4$ buffer (pH 7.4). The sample was mixed,

incubated in the anaerobic chamber at 37°C for 30 min, then on ice 30 min, and removed from the

chamber. The fixed cells were washed twice with 1 mL phosphate-buffered saline (PBS), resuspended

in 50 µl of PBS, and left in the dark for 18 h to allow for chromophore maturation.

MIC determination. Antibiotic sensitivity was determined in 96 well plates. A twofold dilution series of

select antibiotics was prepared in 50 µl TY medium. Wells were then inoculated with 50 µl of a diluted

culture suspension (10^6 CFU/ml; calculated OD_{600} ~0.005). Plates were imaged and evaluated after 17h

at 37°C.

Lysis assay. Cell cultures (1 mL) were removed from the anaerobic chamber, pelleted and resuspended in 700 µL 0.01% Triton X-100 in 50 mM $NaPO_4$ buffer (pH 7.4). Of this 700 µL, three 200 µL replicates were pipetted into wells of a clear, flat bottom 96-well plate. The turbidity was measured at 600 nm every 15 min for 10 h in a plate reader (Tecan Infinite M200 Pro).

Flow cytometry. Cells were analyzed at the Flow Cytometry Facility at the University of Iowa using the Becton, Dickinson LSR II instrument with a 561-nm laser, a 610/20-nm-band-pass filter, and a 600 LP dichroic filter. Data were analyzed using BD FACSDiva software.

Culture growth for RNA-seq samples. To achieve robust, quality data all experiments were performed on three different days for biological replicates. Cultures were grown in 100 mL TY as follows. Wal-ON: to characterize the effect of overexpressing *walR*, strains were subcultured to OD_{600} ~0.05, grown to 0.2, induced with xylose to 3% and grown for an additional 3h (Fig. S4A). Wal-OFF: to characterize the effect of partial knockdown of the *wal* operon under leaky CRISPRi conditions, strains were subcultured to OD_{600} ~0.03 and grown to ~0.7 before harvesting (Fig. S4C). To test the effect of stronger knockdown of the *wal* operon, growth conditions were identified that allowed exposing cells to moderate levels of xylose (0.1%) without a significant loss of biomass. Strains were subcultured to OD_{600} ~0.03, grown to 0.3, diluted back to ~0.1 and induced with xylose to a final concentration of 0.1% and harvested after an additional 2.5 h of growth (Fig. S4D). From each condition, 25 mL culture was fixed by rapidly mixing with 25 mL ice-cold 1:1 ethanol:acetone that had been brought into the anaerobic chamber on dry ice. Fixed cells were stored at -80°C until further workup.

RNA isolation and RNA-Seq. Fixed culture samples were thawed, pelleted for 10 min at 8000 x g, 4°C and pellets washed once with 500 µL 1% β-mercaptoethanol (β-ME) in water. Subsequent steps are an adaptation of the Qiagen RNeasy Mini Kit procedure. The washed pellet was resuspended in 1 mL of the Qiagen-provided RTL buffer amended with 1% β-ME and transferred to a 2 mL screwcap tube filled with

glass beads (0.1 mm diameter) to a height of ~2-3 mm. Cells were lysed with the FastPrep-24

homogenizer with two cycles at 6m/s for 45 s, resting on ice for 3 min between cycles. The homogenized

material was pelleted at 14,000 x g for 15 min at 4°C. The supernatant was removed, adjusted to 900 µL

with RTL/β-ME, mixed with 500 µL ethanol and loaded onto the Qiagen RNeasy spin column. Subsequent

steps followed the manufacturer's protocol. The RNA was eluted with 50 µL water and DNase treated

twice (Ambion Turbo DNA-free). Absence of DNA was evaluated by amplifying a 364 bp region of *mldA*

with Taq DNA polymerase for 30 cycles. The RNA integrity number (RIN) was determined with an Agilent

Bioanalyzer at the Iowa Institute for Human Genetics, Genomics Division. All samples had a RIN of 9.4

or higher. Typical yields from 25 mL culture were 8-20 µg RNA at 200-500 ng/µL.

RNA samples were submitted to the Microbial Genome Sequencing Center (MiGS) in Pittsburgh,

PA. MiGS performed Illumina Stranded RNA library preparation paired with RiboZero Plus (per

manufacturer's specifications) and sequenced on a NextSeq 500 using a 75cyc High Output flowcell.

Fastq files were trimmed and filtered using a combination of Trimmomatic (70) and FastQC

(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Alignment, normalization and differential

expression was analyzed with SeqMan NGen® Version 17.2. DNASTAR, Madison, WI. Annotation was

imported from NCBI with additional information obtained from progenomes (71). All subsequent analysis

was performed in Excel and GraphPad Prism 9.

Bioinformatics. Gene sequences and operon organization were obtained from the BioCyc data

collection (35, 72). SignalP 5.0 (73) was used to search for Type I and Type II signal peptides. BUSCA

(74) was used to predict protein cellular location. When all *C. difficile* proteins were run through the

prediction programs, SignalP predicted ~7% to be exported. BUSCA predicted ~4% to exported and

~25% to be membrane associated. Cell wall association in Tables 2 and 3 was reported as follows: (i)

signal peptidase substrate if predicted by SignalP; (ii) for all remaining genes: membrane protein if

predicted by BUSCA.

Putative WalR binding sites were identified with Virtual Footprint (75) by querying with (1) the *B.*

subtilis consensus motif, TGTWAH-N5-TGTWAH (14), (2) the same motif, but allowing one mismatch, or

(3) TGTNDH-N5-BKBWRN (8). Searches were limited to the intergenic region of the genome and

generated 29, 522, and 684 hits respectively.

Data availability

523 RNA-seq data were submitted to the NCBI GEO repository and assigned accession number GSE200346.

Acknowledgements

This work was supported by National Institutes of Health grants R01AI087834 (CDE) and

R01AI155492 (CDE and DSW) from the National Institutes for Allergy and Infectious Disease. Cell

fluorescence was quantitated at the Flow Cytometry Facility, which is a Carver College of Medicine /

Holden Comprehensive Cancer Center core research facility at the University of Iowa. The facility is

funded through user fees and the generous financial support of the Carver College of Medicine, Holden

Comprehensive Cancer Center, and Iowa City Veteran's Administration Medical Center. RNA integrity

was characterized by the Genomics Division of the Iowa Institute of Human Genetics which is supported,

in part, by the University of Iowa Carver College of Medicine. We thank Nigel Minton for pMTL-YN1C,

Brianne Zbylicki for plasmid pBZ101, and members of the Ellermeier and Weiss laboratories for helpful

discussions.

Table 1. Effect of CRISPRi-silencing *wal* on sensitivity to antibiotics[a]

	MIC [µg/mL]		
	sgRNA-neg	sgRNA-*walA1*	sgRNA-*walA2*
Ampicillin	6.3	3.5	3.1
Imipenem	3.1	3.1	2.6
Vancomycin	4.6	0.9	0.7
Daptomycin	11.3	4.1	5.7
Bacitracin	250	250	250
Novobiocin	13	17	16

539 [a]Results are the average of measurements done in duplicate on four different days.

Table 2. Genes affected by Wal-ON conditions.

Gene, changed ≥ 4-fold	Operon[1]	Gene name	Annotation	Log₂ fold change		CRISPRi against walI[2]	Cell wall association[3]
				WalR overexpression			
				WalR	WalR[D54E]		
cd630_07390	07390		hypothetical protein	5.26	5.70	-1.38	SPI
cd630_15220	15220	pgdA	peptidoglycan deacetylase	4.02	4.26	-1.09	SPI
cd630_05490	05490		hypothetical protein	3.87	4.51	-1.84	SPI
cd630_17820	17810	walA	lipoprotein	nc[4]	nc	-2.76	SPII
	17820	walR	TC response regulator	3.81	3.67	-2.51	
	17830	walK	TC sensor histidine kinase	nc	nc	-2.33	Membrane
	17840	truA2	tRNA pseudouridine synthase A	nc	nc	-2.34	
cd630_07380	07380		hypothetical protein	3.43	4.14	-1.22	SPI
cd630_08670	08670		hypothetical protein	3.28	3.97	nc	Membrane
cd630_07400	07400		PLP dependent aminotransferase	3.21	2.38	nc	
cd630_10880	10880		hypothetical protein	2.88	3.14	-1.40	Membrane
cd630_01660	01660		peptidase	2.76	2.95	nc	
	01650		amino acid transporter	nc	nc	nc	Membrane
cd630_27940	27940	cwp12	cell wall binding protein	2.69	2.82	nc	SPI
cd630_33090	33090	ligA	DNA ligase	2.64	2.62	nc	
cd630_18250	18250	metY	O-acetylhomoserine sulfhydrylase	2.50	2.80	-0.57	
cd630_18260	18260	metA	homoserine O-succinyltransferase	2.60	2.85	-0.88	
cd630_14281	14281		hypothetical protein	2.59	3.22	nc	
cd630_27860	27860	cwp5	cell wall binding protein	2.51	2.65	nc	SPI
cd630_25380	25380		lipoprotein	2.47	2.70	-0.70	SPII
cd630_03910	03910	asnB	asparagine synthetase	2.47	3.30	nc	Membrane
cd630_14960	14960		hypothetical protein	2.37	2.86	-0.74	SPI
cd630_25370	25370		5'-nucleotidase/phosphoesterase	2.33	2.49	-0.59	SPI
cd630_27910	27910	cwp2	cell wall binding protein	2.30	2.36	-0.59	SPI
	27900		LmbE-like deacetylase	1.56	1.46	-0.55	
	27890	cwp66	cell wall binding protein	1.41	1.42	-0.58	SPI
cd630_28620	28620		peptidase	2.29	2.24	-2.53	
cd630_34880	34880	gtaB1	UTP-G1P uridylyltransferase	2.23	2.34	-0.73	
cd630_20580	20580		hypothetical protein	2.22	2.43	-1.26	Membrane
cd630_07410	07410	glpK1	glycerol kinase	2.21	0.63	nc	
	07420	eutH	ethanolamine utilization protein	1.46	nc	nc	Membrane
cd630_10360	10350	cwp16	amidase, cell wall binding protein	1.24	1.33	nc	SPI
	10360	cwp17	amidase, cell wall binding protein	2.15	2.35	nc	SPI
cd630_21170	21170	trxB2	thioredoxin reductase	2.12	2.18	nc	
cd630_00210	00210	pycA	pyruvate carboxylase	2.10	2.16	-0.46	
cd630_13890	13890		chloromuconate cycloisomerase	2.09	2.18	-0.28	
	13900		hypothetical protein	1.30	1.64		Membrane
cd630_22490	22490		ATPase	2.07	2.20	nc	

Gene, changed ≥ 4-fold	Operon[1]	Gene name	Annotation	Log₂ fold change			Cell wall association[3]
				WalR overexpression		CRISPRi against wal[2]	
				WalR	WalR^{D54E}		
cd630_22480	22480		hypothetical protein	1.81	2.04	nc	
cd630_10890	10890	rgbR	TC response regulator	2.04	2.24	-1.13	
	10900	rgbS	TC sensor HK (fragment)	nc	1.16	nc	Membrane
cd630_30930	30930		aminobutyrate hydrolase	2.15	2.35	nc	
	30920		putative amino acid transporter	1.52	1.02	nc	Membrane
cd630_26810	26810		putat. Ca-chelating protein	2.01	2.59	nc	SPI
cd630_36010	36010		D-Alanyl-D-alanine carboxypeptidase	1.99	2.35	-1.38	SPI
cd630_00220	00220		Elongation factor G	1.97	2.09	nc	
cd630_14290	14290		Acyl-CoA N-acyltransferase	1.92	2.47	-1.15	
cd630_22280	22280		Hypothetical protein	1.83	2.05	-0.70	Membrane
cd630_01100	01100		Hypothetical protein	1.81	2.02	nc	Membrane
	01110		Hypothetical protein	1.51	1.73	nc	SPI
	01111		Hypothetical protein	nc	1.14	nc	
cd630_09940	09940		Serine-pyruvate aminotransferase	1.77	2.10	nc	
cd630_19942	19942		Hypothetical protein	1.74	2.12	nc	
cd630_05270	05270		Beta-lactamase-like hydrolase	1.73	2.13	-0.85	
cd630_22270	22270		Radical SAM protein	1.67	2.02	-0.55	SPII
cd630_18070	18070		NADPH-dependent FMN reductase	1.49	2.07	-1.53	Membrane
cd630_03901	03901		Hypothetical protein	0.92	2.37	nc	
cd630_10631	10631		Hypothetical protein	-0.07	2.18	-0.62	Membrane
cd630_30360	30360		Major facilitator superfamily transporter	-1.59	-2.13	1.11	Membrane
cd630_10540	10540	bcd2	Acyl-CoA dehydrogenase	-1.93	-2.23	1.03	
cd630_10550	10550	etfB	Electron transfer flavoprotein beta	-1.78	-2.11	1.07	
cd630_10560	10560	etfA	Electron transfer flavoprotein alpha	-1.95	-2.18	1.10	
cd630_10570	10570	crt2	3-Hydroxybutyryl-CoA dehydratase	-1.96	-2.27	1.06	
cd630_31000	31000		C4-dicarboxylate anaerobic carrier	-1.88	-2.59	nc	Membrane
cd630_30990	30990		Amidohydrolase	-1.80	-2.47	nc	Membrane
cd630_10580	10580	hbd	3-Hydroxybutyryl-CoA dehydrogenase	-1.86	-2.05	0.89	SPII
cd630_10590	10590	thlA1	Acetyl-CoA acetyltransferase	-1.96	-2.16	0.77	
	16820	queK	Queuosine hydrolase monomer	-1.31	-1.60	nc	
	16830		ECF transporter S-comp.	-1.39	-1.65	nc	Membrane
cd630_16840	16840	queL	Radical SAM superfamily protein	-1.90	-2.06	nc	
	23900		BlaI-like	-1.47	-1.65	nc	
cd630_23890	23890		BlaR-like	-1.94	-2.26	0.80	Membrane
	23880		Putat. PG hydrolase	-1.50	-1.77	nc	SPI
	36040		Hypothetical protein	-0.86	-0.94	0.71	
cd630_36030	36030		Phosphoesterase	-1.97	-2.01	1.09	Membrane
cd630_14040	14040		Oligopeptide transporter	-2.02	-2.03	nc	Membrane
	14041		Hypothetical protein	-2.02	-1.88	nc	
	25120		PTS, subunit IIA	-1.11	-1.47	nc	
	25110		PTS, antiterminator	-1.45	-1.46	nc	
cd630_25100	25100		PTS, subunit IIBC	-2.04	-2.19	0.97	Membrane

Gene, changed ≥ 4-fold	Operon[1]	Gene name	Annotation	Log$_2$ fold change			Cell wall association[3]
				WalR overexpression		CRISPRi against *wal*[2]	
				WalR	WalR^{D54E}		
cd630_25320	25320		Alanine-glyoxylate transaminase	-2.05	-2.34	1.41	
cd630_25310	25310		Hypothetical protein	-2.67	-2.75	1.35	Membrane
cd630_27680	27680		Cell-wall hydrolase	-2.06	-2.29	nc	SPI
cd630_29660	29660	*adhE1*	Acetaldehyde-CoA/alcohol dehydrogenase	-2.08	-2.37	-1.09	Membrane
cd630_18120	18120		Response regulator	-2.08	-2.28	nc	
cd630_22600	22600		Major facilitator superfamily transporter	-2.13	-2.32	nc	Membrane
cd630_20160	20160		Hypothetical protein	-2.19	-2.29	4.18	
cd630_25090	25090		Glycoside hydrolase	-2.22	-2.33	1.16	
cd630_21070	21070		Permease family protein	-2.23	-2.32	nc	Membrane
cd630_10220	10220		YczE-like membrane protein	-2.26	-2.73	0.93	Membrane
	10230		Transcriptional regulator	-1.70	-1.94	1.63	
cd630_10240	10240	*potA*	ABC transport ATP-binding protein	-2.27	-2.36	1.77	
cd630_10250	10250	*potB*	ABC transport permease	-2.47	-2.82	1.72	Membrane
cd630_10260	10260	*potC*	ABC transport permease	-2.53	-2.39	1.60	Membrane
cd630_10270	10270	*potD*	ABC transport substrate binding protein	-2.29	-2.37	1.55	SPII
cd630_26640	26640	*murE*	UDP-N-acetylmuramoylalanyl-D-glutamate-2, 6-diaminopimelate ligase	-2.85	-3.07	0.93	
cd630_26670	26670	*ptsG-BC*	PTS, subunit IIBC	-3.17	-3.52	nc	SPI
cd630_26660	26660	*ptsG-A*	PTS, subunit IIA	-3.12	-3.51	nc	
cd630_21510	21510		Hypothetical protein	-3.56	-3.82	0.68	Membrane

[1] Lists other operon members in order

[2] CRISPRi against *wal*: Fold change comparing sgRNA-neg to sgRNA-*walA1* strain in the absence of

xylose

[3] Reports predictions by SignalP (SPI, predicted to be a substrate of signal peptidase I; SPII, predicted

to be a substrate of signal peptidase II) and by BUSCA (membrane). The BUSCA prediction is only given

for those genes that were not already predicted to be SPI or SPII substrates by SignalP.

[4] nc: no change, i.e. the fold change was close to 1 and the P-value >0.05

Abbreviations: TC (two component), PTS (phosphoenolpyruvate-dependent sugar phosphotransferase

system)

Table 3 Genes affected by Wal-OFF conditions

| Gene, changed ≥ 4-fold | Operon[1] | Gene name | Annotation | Log$_2$ fold change | | Cell wall association[3] |
| | | | | CRISPRi | WalR OE[2] | |
				No xyl	Low xyl		
cd630_05140	05140	cwpV	Hemagglutinin/adhesin	4.69	2.74	nc[4]	SPI
cd630_20160	20160		Hypothetical protein	4.18	1.65	-2.19	
cd630_11700	11700		Hypothetical protein	3.52	1.83	nc	
cd630_11710	11710	etfB4	Electron transfer flavoprotein alpha	3.30	1.40	nc	
cd630_11720	11720	etfA4	Electron transfer flavoprotein alpha	2.58	1.24	nc	
cd630_11730	11730		FAD-linked oxidase	2.17	1.08	nc	
cd630_08320	08320	aksA	Trans-homoaconitate synthase	3.11	2.02	nc	
cd630_08330	08330	acnB	Aconitate hydratase	3.06	2.05	nc	
cd630_08340	08340	icd	Isocitrate dehydrogenase	3.07	2.16	nc	
cd630_17290	17290		Sodium:phosphate symporter	2.76	0.45	-1.46	Membrane
cd630_13840	13840		LamB/YcsF family protein	2.17	0.88	nc	
cd630_13850	13850		Hypothetical protein	2.36	1.15	nc	Membrane
cd630_13860	13860		Allophanate hydrolase subunit 1	2.52	1.28	nc	
cd630_13870	13870		Allophanate hydrolase subunit 2	2.60	1.14	nc	
cd630_24260	24260	buk1	Butyrate kinase	2.45	nc	-1.41	
	24250	ptb2	Phosphate butyryltransferase	1.65	nc		
cd630_24240	24240		Pyridoxal phosphate-dependent transferase	2.55	nc	-1.15	
	24230		Putative transporter	1.17	nc		Membrane
cd630_07650	07650	srlEa	PTS, IIB N-terminal component	2.17	nc	nc	
cd630_07660	07660	srlEb	PTS, IIB C-terminal component	2.29	nc	nc	Membrane
cd630_07670	07670	srlB	PTS, IIA subunit	2.27	nc	nc	
cd630_07680	07680	srlD	Sorbitol-6-phosphate dehydrogenase	2.35	nc	nc	
	00350		Transcriptional regulator	1.46	0.55	-0.86	
cd630_00360	00360	acoA	Acetoin dehydrogenase E1 alpha	2.20	0.94	nc	
cd630_00370	00370	acoB	Acetoin dehydrogenase E1 beta	2.29	0.91	nc	
cd630_00380	00380	acoC	Acetoin dehydrogenase E2	2.20	0.72	nc	
cd630_00390	00390	acoL	Acetoin dehydrogenase E3	2.04	0.83	-0.57	
cd630_30010	30010		Hydrolase/isomerase/hydratase	2.25	nc	nc	
cd630_23920	23920		tRNA-binding protein	2.15	1.65	-1.77	
cd630_30960	30960	bglA3	6-Phospho-beta-glucosidase	2.13	nc	nc	
cd630_30950	30950	bglA2	6-Phospho-beta-glucosidase	2.07	nc	nc	
cd630_25150	25150		Aspartate aminotransferase	2.12	2.38	-1.76	

Gene, changed ≥ 4-fold	Operon[1]	Gene name	Annotation	Log$_2$ fold change			Cell wall association[3]
				CRISPRi		WalR OE[2]	
				No xyl	Low xyl		
cd630_24290	24291		Flavo/ferredoxin oxidoreductase delta	1.19	nc	nc	
	24290		Flavo/ferredoxin oxidoreductase alpha	2.11	nc	-0.91	
	24280		Flavo/ferredoxin oxidoreductase beta	1.66	nc	nc	
	24270		Flavo/ferredoxin oxidoreductase gamma	1.50	nc	nc	
cd630_30040	30040	kdgT2	2-Keto-3-deoxygluconate permease	2.08	0.33	0.93	Membrane
cd630_30020	30020	uxaA	D-galactate dehydratase/altronate hydrolase	2.06	0.25	nc	
cd630_32630	32630	pstC	Phosphate ABC transporter, PstC	2.03	nc	nc	Membrane
	32620	pstA	Phosphate ABC transporter, PstA	1.03	nc	nc	Membrane
	32610	pstB	Phosphate ABC transporter, ATP binding	1.80	nc	nc	
	32600	phoU	Phosphate uptake regulator	1.25	nc	nx	
	30980	bglG1	PTS, antiterminator	0.95	nc	nc	
cd630_30970	30970	bglF2	PTS, subunit IIABC	2.01	nc	-0.76	Membrane
cd630_28540	28540	dltD	D-alanine transferase	-1.52	-2.41	1.03	Membrane
cd630_28530	28530	dltA	D-ala-D-ala carrier protein ligase 1	-1.34	-2.27	0.84	
cd630_28520	28520	dltB	D-alanyl transferase	-1.34	-2.23	0.49	Membrane
	28510	dltC	D-ala-D-ala carrier protein ligase 2	-1.27	-1.89	nc	
cd630_09000	09000	opuCA	ABC transporter ATP-binding protein	-1.69	-2.36	1.46	
cd630_09010	09010	opuCC	ABC transporter permease	-1.68	-2.40	1.27	Membrane
cd630_05190	05190		Hypothetical protein	-2.00	-2.59	0.57	Membrane
	05260		Aminobenzoyl-glutamate transporter	nd[5]	nd	nd	
cd630_05250	05250		Peptidase	-2.15	-1.08	nc	
cd630_17671	17671		Hypothetical protein	-2.18	-1.99	nc	
cd630_17680	17680		Membrane protein	-2.23	-2.18	0.56	Membrane
cd630_17810	17810	walA	Lipoprotein	-2.76	-5.14	nc	SPII
cd630_17820	17820	walR	TC response regulator	-2.51	-3.91	3.81	
cd630_17830	17830	walK	TC sensor histidine kinase	-2.33	-4.03	nc	Membrane
cd630_17840	17840	truA2	tRNA pseudouridine synthase A	-2.34	-3.92	nc	
cd630_05300	05300		Membrane protein	-2.47	nc	nc	Membrane
	05290		Membrane protein	nc	nc	nc	Membrane
	05280		Amidohydrolase	nc	nc	0.92	
cd630_28620	28620		Peptidase	-2.53	-1.43	2.29	

[1] Lists other operon members in order

[2] Fold change comparing WalR overexpression to negative control strain

[3] Predictions by SignalP (SPI, predicted to be a substrate of signal peptidase I; SPII, predicted to be a

substrate of signal peptidase II) and by BUSCA (membrane). The BUSCA prediction is only given for

those genes that were not already predicted to be SPI or SPII substrates by SignalP.

[4] nc: no change, i.e. the fold change was close to 1 and the P-value >0.05

[5] nd: CD630_05260 is a pseudogene that was not detected by the RNA-seq analysis tool

Abbreviations: TC (two component), PTS (phosphoenolpyruvate-dependent sugar phosphotransferase

system)

Table 4 Strains used in this study

Strain	Genotype and/or description	Source or reference
E. coli		
OmniMAX-2 T1^R	F′ [*proAB$^+$ lacI^q lacZ*ΔM15 Tn*10*(Tet^R) Δ(*ccdAB*)] *mcrA* Δ(*mrr-hsdRMS-mcrBC*) φ80(*lacZ*)ΔM15 Δ(*lacZYA-argF*) *U169 endA1 recA1 supE44 thi-1 gyrA96 relA1 tonA panD*	Invitrogen
HB101/pRK24	F− *mcrB mrr hsdS20*(r$_B$⁻ m$_B$⁻) *recA13 leuB6 ara-14 proA2 lacY1 galK2 xyl-5 mtl-1 rpsL20*	(66, 67)
C. difficile		
R20291	Wild-type *C. difficile strain* from UK outbreak (ribotype 027)	
630Δ*erm*	Spontaneous erythromycin-sensitive derivative of strain 630 (ribotype 012)	(76)
CRG1496	630Δ*erm*Δ*pyrE*	(29)
UM275	630Δ*erm* with P$_{veg}$::*rfp* downstream of *pyrE*	(26)
UM554	630Δ*erm* with P$_{xyl}$::*dCas9* P$_{gdh}$::*sgRNA*-neg downstream of *pyrE*	This study
UM555	630Δ*erm* with P$_{xyl}$::*dCas9* P$_{gdh}$::*sgRNA-walA-1* downstream of *pyrE*	This study
UM556	630Δ*erm* with P$_{xyl}$::*dCas9* P$_{gdh}$::*sgRNA-walA-2* downstream of *pyrE*	This study
UM626	630Δ*erm* with P$_{xyl}$::*walR* downstream of *pyrE*	This study
UM628	630Δ*erm* with P$_{xyl}$::*walR^{D54E}* downstream of *pyrE*	This study
UM926	630Δ*erm* with P$_{cd630\_0739}$::*mCherryOpt* downstream of *pyrE*	This study

569 **Table 5.** Plasmids used in this study

Plasmid	Relevant features	Reference or comment
pAP114	P$_{xyl}$::*mCherryOpt catP*	(26)
pBZ101	P$_{xyl}$ empty vector	This study
pCE636	P$_{dltD}$::*mCherryOpt catP*	This study
pCE738	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-dltD-1 catP*	(37)
pCE691	P$_{xyl}$::*walR catP*	This study
pCE738	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-dltD-1 catP*	(37)
pCE741	P$_{xyl}$::*cdr2656*	This study
pCE744	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-cd630_27680-1 catP*	This study
pCE745	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-cd630_27680-2 catP*	This study
pCE789	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*cwpV-1 catP*	This study
pCE791	P$_{xyl}$::*cwpV*	This study
pDSW1728	P$_{tet}$::*mCherryOpt catP*	(55)
pDSW2037	P$_{xyl}$ in integration vector pMTL-YN1C *catP*	This study
pDSW2053	P$_{xyl}$::*dCas9opt-*P$_{gdh}$::*sgRNA-neg* in pMTL-YN1C *catP*	This study
pDSW2055	P$_{xyl}$::*dCas9opt-*P$_{gdh}$::*sgRNA-cd630_17810-1* in pMTL-YN1C *catP*	This study
pDSW2057	P$_{xyl}$::*dCas9opt-*P$_{gdh}$::*sgRNA-cd630_17810-2* in pMTL-YN1C *catP*	This study
pIA33	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-rfp catP*	(26)
pIA34	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-neg catP*	(26)
pIA50	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-walA-1 catP*	This study
pIA51	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*sgRNA-walA-2 catP*	This study
pIA75	P$_{xyl}$::*walR* in pMTL-YN1C *catP*	This study
pIA76	P$_{xyl}$:*walR*^{D54E} in pMTL-YN1C *catP*	This study
pIA79	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*cd630_25040-1 catP*	This study
pIA80	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*cd630_25040-2 catP*	This study
pIA81	P$_{xyl}$::*dCas9-opt* P$_{gdh}$::*cd630_36010-1 catP*	This study
pIA93	P$_{cdr\_0665}$::*mCherryOpt catP*	This study; *cdr_0665* is ortholog of *cd630_07380*

pIA95	P*cdr_0796*::*mCherryOpt catP*	This study; *cdr_0796* is ortholog of *cd630_08670*
pIA97	P*cdr_2753*::*mCherryOpt catP*	This study; *cdr_2753* is ortholog of *cd630_28620*
pIA98	P*cdr_0455*::*mCherryOpt catP*	This study; *cdr_0455* is ortholog of *cd630_53000*
pIA100	P*cd630_0739*::*mCherryOpt catP*	This study
pIA101	P*cd630_0739*::*mCherryOpt* in pMTL-YN1C *catP*	This stduy
pIA102	P*xyl*::*dCas9-opt* P*gdh*::*cd630_05490 catP*	This study
pIA103	P*xyl*::*dCas9-opt* P*gdh*::*cd630_27940 catP*	This study
pIA104	P*xyl*::*dCas9-opt* P*gdh*::*cd630_27860 catP*	This study
pIA105	P*xyl*::*dCas9-opt* P*gdh*::*cd630_27910 catP*	This study
pIA106	P*xyl*::*dCas9-opt* P*gdh*::*cd630_10360 catP*	This study
pIA107	P*pgdA*::*mCherryOpt catP*	This study
pIA108	P*xyl*::*dCas9-opt* P*gdh*::*cd630_07380-1 catP*	This study
pIA109	P*xyl*::*dCas9-opt* P*gdh*::*cd630_07380-2 catP*	This study
pIA110	P*xyl*::*dCas9-opt* P*gdh*::*cd630_07390-1 catP*	This study
pIA111	P*xyl*::*dCas9-opt* P*gdh*::*cd630_07390-2 catP*	This study
pIA112	P*xyl*::*cd630_0738*	This study
pIA113	P*xyl*::*cd630_0739*	This study
pIA114	P*xyl*::*cd630_0738-cd630_0739*	This study
pIA115	P*xyl*::*cd630_0739-cd630_0738*	This study
pMTL-YN1C	*E. coli-C. difficile* shuttle vector for inserting genes into *C. difficile* chromosome while restoring *pyrE*; c*olE1 RP4oriT-TraJ CB102ori-repH' catP*	(29)

Legends

Fig. 1. The *wal* operon of *C. difficile*. Based on studies in other bacteria, WalK (red) is a bifunctional signal transducing enzyme that can phosphorylate or dephosphorylate WalR (green). WalK is predicted to have an extracellular Cache domain, as well as intracellular HAMP, HisKA (phospho-acceptor), and HATPase domains. Unlike the *B. subtilis* ortholog (inset), it does not have an intracellular PAS domain. WalR~P binds DNA to activate or repress expression of Wal-regulated genes. The lipoprotein (WalA, blue), which is unique to *C. difficile*, may modulate WalK activity and is predicted to have a beta-propeller lyase domain. The *truA2* gene codes for a pseudouridylate synthase and is not thought to play a role in Wal signaling. Operon locus: *cdr20291_1676-1679* in R20291 and *cd630_17810-17840* in 630Δerm.

Fig. 2. The *wal* operon is required for viability and normal rod morphology of *C. difficile* 630Δerm. (A) Viability assay. Serial dilutions of overnight cultures were spotted onto TY plates with or without 1% xylose to induce the expression of *dCas9*. Plates were photographed after incubation overnight. Strains carry chromosomal copies of the CRISPRi components and the following guides: sgRNA-neg (UM554), sgRNA-*walA1* (UM555), and sgRNA-*walA2* (UM556). (B) Growth curves in liquid TY containing 0, 0.01, 0.1 or 1% xylose as indicated. For clarity, the sgRNA-neg control strain is graphed only at 0 xylose. Samples were taken at 4 hours (arrow) for phase contrast microscopy (C), cell length measurements (D) and determination of curvature (E). Numbers at the bottom of micrographs in (C) refer to % xylose. Note cell debris indicative of lysis at 1% xylose. Bar = 10 μm. Cell length and percent curved cells were based on about 500 cells per condition. The sgRNA-*walA1* strain is longer than the sgRNA-neg control in all pairwise comparisons as determined by a T-test, $p < 0.0001$.

Fig. 3. Overexpression of *walR* from a multi-copy plasmid impairs growth, alters morphology and slows autolysis in 630Δerm. A. Viability assay. Overnight cultures of 630Δerm harboring pCE691 (P_{xyl}::*walR*) or the empty vector control plasmid pBZ101 (P_{xyl} EV) were serially diluted and spotted onto TY-Thi plates with or without 1% xylose. Plates were photographed after incubation overnight. (B) Growth

curve of 630Δerm/pCE691 (P$_{xyl}$::*walR*). Duplicate cultures were grown to an OD$_{600}$ of 0.2, at which time

one was induced with 3% xylose (green arrow). Both cultures were harvested after 3h (red arrow) for

analysis by phase contrast microscopy (C) and a lysis assay (D). Bar in (C) = 10 µm. For the lysis assay,

cells were suspended in buffer containing 0.01% Triton X-100 and OD$_{600}$ was monitored over time. Error

bars depict SD of 3 technical replicates. Data shown are representative of at least 3 independent

experiments.

Fig. 4. Prolonged overexpression of *walR* from a single-copy chromosomal P$_{xyl}$::*walR* allele

affects cell shape and slows lysis. (A) Growth curves. An overnight culture of strain UM626 (P$_{xyl}$::*walR*

integrated at *pyrE* in 630Δerm) was subcultured 1:50 into TY with varied xylose concentrations as

indicated and grown for 6 hours, then analyzed in a lysis assay (B) or by phase contrast microscopy (C).

For the lysis assay, cells were suspended in buffer containing 0.01% Triton X-100 and OD$_{600}$ was

monitored over time. Data are graphed as the mean and SD of 3 technical replicates, but most error bars

are smaller than the symbols. Cells from cultures grown in the presence of 0-1% xylose appeared normal

and are not shown, but in cultures induced with 3% xylose about 10% of the cells had irregular or bent

morphologies, examples of which are shown in (C). Bar = 10 µm. Data shown are representative of at

least 3 independent experiments.

Fig. 5. Comparison of transcript changes between Wal-ON and Wal-OFF conditions. (A). Heatmap

showing the 79 genes whose transcript abundance changed $\geq$ 4-fold when *walR* was overexpressed

(Wal-ON) in comparison to when the *wal* operon was silenced with CRISPRi (Wal-OFF). (B) Heatmap

showing the 49 genes whose transcript abundance changed $\geq$ 4-fold when the *wal* operon was silenced

(Wal-OFF) in comparison to when *walR* was overexpressed (Wal-ON). Green, induced. Red, repressed.

Fig. 6. Confirmation of RNA-seq results with RFP reporter fusions to select genes. Cells harboring plasmids with transcriptional fusions of the red fluorescent protein mCherryOpt to the indicated promoters were grown as per RNA-seq conditions, either Wal-ON (green) or Wal-OFF (red). Red fluorescence was measured by flow cytometry and is graphed as the mean log2-fold change from two independent experiments with two technical replicates. Error bars represent the SD of all four measurements. For comparison, the mean log2-fold change of the same genes as determined by RNA-seq is also shown. The *dltD* reporter is graphed only under Wal-OFF conditions because this fusion was induced by xylose even in the absence of $P_{xyl}::walR$. Genes with asterisks denote fusions that were constructed to the corresponding promoter regions from strain R20291.

Fig. 7. Perturbation of individual Wal-ON regulon genes does not replicate the Wal-ON phenotype. Overnight cultures of 630Δerm harboring overexpression plasmids were subcultured into TY-Thi to an OD_{600} of 0.03, grown to OD_{600} = 0.2 and induced with 3% xylose for 3h. Overnight cultures of 630Δerm harboring CRISPRi plasmids were subcultured into TY-Thi containing 1% xylose to an OD_{600} of 0.03 and grown to OD_{600} ~0.8. Each culture was then (A) examined by microscopy (bar 5 μm) and (B) tested in the lysis assay. Induction of *walR* is the only condition that achieved phase bright cells and slowed lysis. The plasmids used were: pBZ101 (EV), pCE691 ($P_{xyl}::walR$), pIA112 ($P_{xyl}::cd630\_07380$), pIA113 ($P_{xyl}::cd630\_07390$), pIA114 ($P_{xyl}::cd630\_07380-07390$), pIA115 ($P_{xyl}::cd630\_07390-07380$), pIA34 (sgRNA-neg), pCE744 (*sgRNA-cd630_27680-1*), and pCE745 (*sgRNA-cd630_27680-2*).

Fig. 8. Perturbation of individual Wal-OFF regulon genes does not replicate the Wal-OFF phenotype. (A) Phase contrast microscopy of strains harboring overexpression plasmids or CRISPRi plasmids after induction with xylose as described in the legend to Fig. 7. Bar = 5 μm. (B) Viability assay. Overnight cultures were serially diluted and spotted onto TY plates with or without 1% xylose. Plates were photographed after incubation overnight. CRISRPi knockdown of the *wal* operon was the only

650   condition that resulted in curved cells, lysis or a viability defect. The plasmids used were pBZ101 (EV),

651   pCE791 (P*xyl*::*cwpV*), pIA34 (sgRNA-neg), pIA50 (sgRNA-*walA1*), and pCE738 (sgRNA-*dltD*).

References

1.   Rohs PDA, Bernhardt TG. 2021. Growth and Division of the Peptidoglycan Matrix. Annu Rev Microbiol
75:315-336.
2.   Fabret C, Hoch JA. 1998. A two-component signal transduction system essential for growth of *Bacillus*
subtilis: implications for anti-infective therapy. J Bacteriol 180:6375-83.
3.   Martin PK, Li T, Sun D, Biek DP, Schmid MB. 1999. Role in cell permeability of an essential two-
component system in *Staphylococcus aureus*. J Bacteriol 181:3666-73.
4.   Dubrac S, Msadek T. 2004. Identification of genes controlled by the essential YycG/YycF two-component
system of *Staphylococcus aureus*. J Bacteriol 186:1175-81.
5.   Dubrac S, Boneca IG, Poupel O, Msadek T. 2007. New insights into the WalK/WalR (YycG/YycF) essential
signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm
formation in *Staphylococcus aureus*. J Bacteriol 189:8257-69.
6.   Ng WL, Robertson GT, Kazmierczak KM, Zhao J, Gilmour R, Winkler ME. 2003. Constitutive expression of
PcsB suppresses the requirement for the essential VicR (YycF) response regulator in *Streptococcus*
pneumoniae R6. Mol Microbiol 50:1647-63.
7.   Ng WL, Kazmierczak KM, Winkler ME. 2004. Defective cell wall synthesis in *Streptococcus pneumoniae*
R6 depleted for the essential PcsB putative murein hydrolase or the VicR (YycF) response regulator. Mol
Microbiol 53:1161-75.
8.   Dubrac S, Bisicchia P, Devine KM, Msadek T. 2008. A matter of life and death: cell wall homeostasis and
the WalKR (YycGF) essential signal transduction pathway. Mol Microbiol 70:1307-22.
9.   Dubrac S, Msadek T. 2008. Tearing down the wall: peptidoglycan metabolism and the WalK/WalR
(YycG/YycF) essential two-component system. Adv Exp Med Biol 631:214-28.
10.   Takada H, Yoshikawa H. 2018. Essentiality and function of WalK/WalR two-component system: the past,
present, and future of research. Biosci Biotechnol Biochem doi:10.1080/09168451.2018.1444466:1-11.
11.   Dobihal GS, Brunet YR, Flores-Kim J, Rudner DZ. 2019. Homeostatic control of cell wall hydrolysis by the
WalRK two-component signaling pathway in Bacillus subtilis. Elife 8.
12.   Bisicchia P, Noone D, Lioliou E, Howell A, Quigley S, Jensen T, Jarmer H, Devine KM. 2007. The essential
YycFG two-component system controls cell wall metabolism in *Bacillus subtilis*. Mol Microbiol 65:180-
200.
13.   Delauné A, Dubrac S, Blanchet C, Poupel O, Mader U, Hiron A, Leduc A, Fitting C, Nicolas P, Cavaillon JM,
Adib-Conquy M, Msadek T. 2012. The WalKR system controls major staphylococcal virulence genes and
is involved in triggering the host inflammatory response. Infect Immun 80:3438-53.
14.   Howell A, Dubrac S, Andersen KK, Noone D, Fert J, Msadek T, Devine K. 2003. Genes controlled by the
essential YycG/YycF two-component system of *Bacillus subtilis* revealed through a novel hybrid regulator
approach. Mol Microbiol 49:1639-55.
15.   Liu X, Gallay C, Kjos M, Domenech A, Slager J, van Kessel SP, Knoops K, Sorg RA, Zhang JR, Veening JW.
2017. High-throughput CRISPRi phenotyping identifies new essential genes in *Streptococcus*
pneumoniae. Mol Syst Biol 13:931.
16.   Ng WL, Tsui HC, Winkler ME. 2005. Regulation of the pspA virulence factor and essential pcsB murein
biosynthetic genes by the phosphorylated VicR (YycF) response regulator in *Streptococcus pneumoniae*. J
Bacteriol 187:7444-59.

17. Delaune A, Poupel O, Mallet A, Coic YM, Msadek T, Dubrac S. 2011. Peptidoglycan crosslinking relaxation
plays an important role in *Staphylococcus aureus* WalKR-dependent cell viability. PLoS One 6:e17054.
18. Takada H, Shiwa Y, Takino Y, Osaka N, Ueda S, Watanabe S, Chibazakura T, Su'etsugu M, Utsumi R,
Yoshikawa H. 2018. Essentiality of WalRK for growth in *Bacillus subtilis* and its role during heat stress.
Microbiology (Reading) 164:670-684.
19. CDC. 2019. Antibiotic Resistance Threats in the United States.
20. Fagan RP, Albesa-Jove D, Qazi O, Svergun DI, Brown KA, Fairweather NF. 2009. Structural insights into
the molecular organization of the S-layer from *Clostridium difficile*. Mol Microbiol 71:1308-22.
21. Fagan RP, Fairweather NF. 2014. Biogenesis and functions of bacterial S-layers. Nat Rev Microbiol
12:211-22.
22. Kirk JA, Banerji O, Fagan RP. 2017. Characteristics of the *Clostridium difficile* cell envelope and its
importance in therapeutics. Microb Biotechnol 10:76-90.
23. Peltier J, Courtin P, El Meouche I, Lemee L, Chapot-Chartier MP, Pons JL. 2011. *Clostridium difficile* has
an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-
3 cross-links. J Biol Chem 286:29053-62.
24. Nguyen HT, Wolff KA, Cartabuke RH, Ogwang S, Nguyen L. 2010. A lipoprotein modulates activity of the
MtrAB two-component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall
homeostasis in *Mycobacterium*. Mol Microbiol 76:348-64.
25. Winkler ME, Hoch JA. 2008. Essentiality, bypass, and targeting of the YycFG (VicRK) two-component
regulatory system in gram-positive bacteria. J Bacteriol 190:2645-8.
26. Müh U, Pannullo AG, Weiss DS, Ellermeier CD. 2019. A xylose-inducible expression system and a CRISPRi-
plasmid for targeted knock-down of gene expression in *Clostridioides difficile*. J Bacteriol
doi:10.1128/jb.00711-18.
27. Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M, Lawley TD, Fairweather NF, Fagan RP. 2015. High-
throughput analysis of gene essentiality and sporulation in *Clostridium difficile*. MBio 6:e02383.
28. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. 2013. Repurposing CRISPR as
an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173-83.
29. Ng YK, Ehsaan M, Philip S, Collery MM, Janoir C, Collignon A, Cartman ST, Minton NP. 2013. Expanding
the repertoire of gene tools for precise manipulation of the *Clostridium difficile* genome: allelic exchange
using *pyrE* alleles. PLoS One 8:e56051.
30. Fukuchi K, Kasahara Y, Asai K, Kobayashi K, Moriya S, Ogasawara N. 2000. The essential two-component
regulatory system encoded by *yycF* and *yycG* modulates expression of the *ftsAZ* operon in *Bacillus
subtilis*. Microbiology (Reading) 146 (Pt 7):1573-1583.
31. Camiade E, Peltier J, Bourgeois I, Couture-Tosi E, Courtin P, Antunes A, Chapot-Chartier MP, Dupuy B,
Pons JL. 2010. Characterization of Acp, a peptidoglycan hydrolase of *Clostridium perfringens* with N-
acetylglucosaminidase activity that is implicated in cell separation and stress-induced autolysis. J
Bacteriol 192:2373-84.
32. Neuhaus FC, Baddiley J. 2003. A continuum of anionic charge: structures and functions of D-alanyl-
teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev 67:686-723.
33. Lan CY, Igo MM. 1998. Differential expression of the OmpF and OmpC porin proteins in *Escherichia coli*
K-12 depends upon the level of active OmpR. J Bacteriol 180:171-4.
34. Smith JG, Latiolais JA, Guanga GP, Pennington JD, Silversmith RE, Bourret RB. 2004. A search for amino
acid substitutions that universally activate response regulators. Mol Microbiol 51:887-901.
35. Caspi R, Billington R, Ferrer L, Foerster H, Fulcher CA, Keseler IM, Kothari A, Krummenacker M,
Latendresse M, Mueller LA, Ong Q, Paley S, Subhraveti P, Weaver DS, Karp PD. 2016. The MetaCyc
database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases.
Nucleic Acids Res 44:D471-80.

36.   Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T. 2020. Peptidoglycan analysis reveals that
742   synergistic deacetylase activity in vegetative *Clostridium difficile* impacts the host response. J Biol Chem
743   295:16785-16796.
744   37.   Kaus GM, Snyder LF, Müh U, Flores MJ, Popham DL, Ellermeier CD. 2020. Lysozyme Resistance in
745   *Clostridioides difficile* Is Dependent on Two Peptidoglycan Deacetylases. J Bacteriol 202.
746   38.   Ammam F, Patin D, Coullon H, Blanot D, Lambert T, Mengin-Lecreulx D, Candela T. 2020. AsnB is
747   responsible for peptidoglycan precursor amidation in *Clostridium difficile* in the presence of vancomycin.
748   Microbiology (Reading) 166:567-578.
749   39.   Dajkovic A, Tesson B, Chauhan S, Courtin P, Keary R, Flores P, Marlière C, Filipe SR, Chapot-Chartier MP,
750   Carballido-Lopez R. 2017. Hydrolysis of peptidoglycan is modulated by amidation of meso-
751   diaminopimelic acid and Mg(2+) in *Bacillus subtilis*. Mol Microbiol 104:972-988.
752   40.   Eveland SS, Pompliano DL, Anderson MS. 1997. Conditionally lethal *Escherichia coli* murein mutants
753   contain point defects that map to regions conserved among murein and folyl poly-gamma-glutamate
754   ligases: identification of a ligase superfamily. Biochemistry 36:6223-9.
755   41.   Bradshaw WJ, Roberts AK, Shone CC, Acharya KR. 2018. The structure of the S-layer of *Clostridium
756   difficile*. J Cell Commun Signal 12:319-331.
757   42.   Layec S, Decaris B, Leblond-Bourget N. 2008. Diversity of Firmicutes peptidoglycan hydrolases and
758   specificities of those involved in daughter cell separation. Res Microbiol 159:507-15.
759   43.   Ho TD, Williams KB, Chen Y, Helm RF, Popham DL, Ellermeier CD. 2014. *Clostridium difficile*
760   extracytoplasmic function sigma factor sigmaV regulates lysozyme resistance and is necessary for
761   pathogenesis in the hamster model of infection. Infect Immun 82:2345-55.
762   44.   Donahue EH, Dawson LF, Valiente E, Firth-Clark S, Major MR, Littler E, Perrior TR, Wren BW. 2014.
763   *Clostridium difficile* has a single sortase, SrtB, that can be inhibited by small-molecule inhibitors. BMC
764   Microbiol 14:219.
765   45.   Amoroso A, Boudet J, Berzigotti S, Duval V, Teller N, Mengin-Lecreulx D, Luxen A, Simorre JP, Joris B.
766   2012. A peptidoglycan fragment triggers β-lactam resistance in *Bacillus licheniformis*. PLoS Pathog
767   8:e1002571.
768   46.   Sandhu BK, Edwards AN, Anderson SE, Woods EC, McBride SM. 2019. Regulation and Anaerobic
769   Function of the *Clostridioides difficile* β-Lactamase. Antimicrob Agents Chemother 64.
770   47.   Zhou Q, Rao F, Chen Z, Cheng Y, Zhang Q, Zhang J, Guan Z, He Y, Yu W, Cui G, Qi X, Hong W. 2022. The
771   cwp66 Gene Affects Cell Adhesion, Stress Tolerance, and Antibiotic Resistance in *Clostridioides difficile*.
772   Microbiol Spectr doi:10.1128/spectrum.02704-21:e0270421.
773   48.   Dhiman A, Bhatnagar S, Kulshreshtha P, Bhatnagar R. 2014. Functional characterization of WalRK: A two-
774   component signal transduction system from *Bacillus anthracis*. FEBS Open Bio 4:65-76.
775   49.   Woods EC, Nawrocki KL, Suárez JM, McBride SM. 2016. The *Clostridium difficile* Dlt Pathway Is
776   Controlled by the Extracytoplasmic Function Sigma Factor σ^V in Response to Lysozyme. Infect Immun
777   84:1902-1916.
778   50.   Fischer W, Rösel P, Koch HU. 1981. Effect of alanine ester substitution and other structural features of
779   lipoteichoic acids on their inhibitory activity against autolysins of *Staphylococcus aureus*. J Bacteriol
780   146:467-75.
781   51.   Wecke J, Perego M, Fischer W. 1996. D-alanine deprivation of *Bacillus subtilis* teichoic acids is without
782   effect on cell growth and morphology but affects the autolytic activity. Microb Drug Resist 2:123-9.
783   52.   McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for antimicrobial peptide
784   resistance in *Clostridium difficile*. Infect Immun 79:167-76.
785   53.   Peschel A, Vuong C, Otto M, Götz F. 2000. The D-alanine residues of *Staphylococcus aureus* teichoic
786   acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents
787   Chemother 44:2845-7.

54.   Sekulovic O, Ospina Bedoya M, Fivian-Hughes AS, Fairweather NF, Fortier LC. 2015. The *Clostridium*
difficile cell wall protein CwpV confers phase-variable phage resistance. Mol Microbiol 98:329-42.

55.   Ransom EM, Ellermeier CD, Weiss DS. 2015. Use of mCherry Red fluorescent protein for studies of
protein localization and gene expression in *Clostridium difficile*. Appl Environ Microbiol 81:1652-60.

56.   Fuchs M, Lamm-Schmidt V, Sulzer J, Ponath F, Jenniches L, Kirk JA, Fagan RP, Barquist L, Vogel J, Faber F.
2021. An RNA-centric global view of *Clostridioides difficile* reveals broad activity of Hfq in a clinically
important gram-positive bacterium. Proc Natl Acad Sci U S A 118.

57.   Dobihal GS, Flores-Kim J, Roney IJ, Wang X, Rudner DZ. 2021. The WalR-WalK signaling pathway
modulates the activities of both CwlO and LytE through control of the peptidoglycan deacetylase PdaC in
Bacillus subtilis. J Bacteriol doi:10.1128/jb.00533-21:Jb0053321.

58.   Jansen A, Türck M, Szekat C, Nagel M, Clever I, Bierbaum G. 2007. Role of insertion elements and yycFG
in the development of decreased susceptibility to vancomycin in *Staphylococcus aureus*. Int J Med
Microbiol 297:205-15.

59.   McEvoy CR, Tsuji B, Gao W, Seemann T, Porter JL, Doig K, Ngo D, Howden BP, Stinear TP. 2013.
Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR
expression. Antimicrob Agents Chemother 57:3240-9.

60.   Hu J, Zhang X, Liu X, Chen C, Sun B. 2015. Mechanism of reduced vancomycin susceptibility conferred by
walK mutation in community-acquired methicillin-resistant *Staphylococcus aureus* strain MW2.
Antimicrob Agents Chemother 59:1352-5.

61.   Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S, Hu X, Li M, Rao X. 2017.
WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108. J
Antimicrob Chemother 72:1006-1013.

62.   Hu Q, Peng H, Rao X. 2016. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin
Intermediate *Staphylococcus aureus*. Front Microbiol 7:1601.

63.   Mesnage S, Dellarole M, Baxter NJ, Rouget JB, Dimitrov JD, Wang N, Fujimoto Y, Hounslow AM, Lacroix-
Desmazes S, Fukase K, Foster SJ, Williamson MP. 2014. Molecular basis for bacterial peptidoglycan
recognition by LysM domains. Nat Commun 5:4269.

64.   Rice KC, Bayles KW. 2008. Molecular control of bacterial death and lysis. Microbiol Mol Biol Rev 72:85-
109, table of contents.

65.   Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, 3rd, Smith HO. 2009. Enzymatic assembly of
DNA molecules up to several hundred kilobases. Nat Methods 6:343-5.

66.   Dineen SS, Villapakkam AC, Nordman JT, Sonenshein AL. 2007. Repression of *Clostridium difficile* toxin
gene expression by CodY. Mol Microbiol 66:206-19.

67.   Trieu-Cuot P, Carlier C, Poyart-Salmeron C, Courvalin P. 1991. Shuttle vectors containing a multiple
cloning site and a lacZ alpha gene for conjugal transfer of DNA from *Escherichia coli* to gram-positive
bacteria. Gene 102:99-104.

68.   Kirk JA, Fagan RP. 2016. Heat shock increases conjugation efficiency in *Clostridium difficile*. Anaerobe
42:1-5.

69.   Ducret A, Quardokus EM, Brun YV. 2016. MicrobeJ, a tool for high throughput bacterial cell detection
and quantitative analysis. Nat Microbiol 1:16077.

70.   Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data.
Bioinformatics 30:2114-20.

71.   Mende DR, Letunic I, Huerta-Cepas J, Li SS, Forslund K, Sunagawa S, Bork P. 2017. proGenomes: a
resource for consistent functional and taxonomic annotations of prokaryotic genomes. Nucleic Acids Res
45:D529-d534.

72.   Caspi R, Altman T, Billington R, Dreher K, Foerster H, Fulcher CA, Holland TA, Keseler IM, Kothari A, Kubo
A, Krummenacker M, Latendresse M, Mueller LA, Ong Q, Paley S, Subhraveti P, Weaver DS, Weerasinghe

D, Zhang P, Karp PD. 2014. The MetaCyc database of metabolic pathways and enzymes and the BioCyc

collection of Pathway/Genome Databases. Nucleic Acids Res 42:D459-71.

73. Almagro Armenteros JJ, Tsirigos KD, Sonderby CK, Petersen TN, Winther O, Brunak S, von Heijne G,

Nielsen H. 2019. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat

Biotechnol 37:420-423.

74. Savojardo C, Martelli PL, Fariselli P, Profiti G, Casadio R. 2018. BUSCA: an integrative web server to

predict subcellular localization of proteins. Nucleic Acids Res 46:W459-w466.

75. Münch R, Hiller K, Grote A, Scheer M, Klein J, Schobert M, Jahn D. 2005. Virtual Footprint and

PRODORIC: an integrative framework for regulon prediction in prokaryotes. Bioinformatics 21:4187-9.

76. Hussain HA, Roberts AP, Mullany P. 2005. Generation of an erythromycin-sensitive derivative of

Clostridium difficile strain 630 (630Δ*erm*) and demonstration that the conjugative transposon Tn*916*ΔE

enters the genome of this strain at multiple sites. J Med Microbiol 54:137-41.

Fig. 1. The *wal* operon of *C. difficile*. Based on studies in other bacteria, WalK (red) is a bifunctional signal transducing enzyme that can phosphorylate or dephosphorylate WalR (green). WalK is predicted to have an extracellular Cache domain, as well as intracellular HAMP, HisKA (phospho-acceptor), and HATPase domains. Unlike the *B. subtilis* ortholog (inset), it does not have an intracellular PAS domain. WalR~P binds DNA to activate or repress expression of Wal-regulated genes. The lipoprotein (WalA, blue), which is unique to *C. difficile*, may modulate WalK activity and is predicted to have a beta-propeller lyase domain. The *truA2* gene codes for a pseudouridylate synthase and is not thought to play a role in Wal signaling. Operon locus: *cdr20291_1676-1679* in R20291 and *cd630_17810-17840* in 630Δerm.

Fig. 2. The *wal* operon is required for viability and normal rod morphology of *C. difficile* 630Δerm. (A) Viability assay. Serial dilutions of overnight cultures were spotted onto TY plates with or without 1% xylose to induce the expression of *dCas9*. Plates were photographed after incubation overnight. Strains carry chromosomal copies of the CRISPRi components and the following guides: sgRNA-neg (UM554), sgRNA-*walA1* (UM555), and sgRNA-*walA2* (UM556). (B) Growth curves in liquid TY containing 0, 0.01, 0.1 or 1% xylose as indicated. For clarity, the sgRNA-neg control strain is graphed only at 0 xylose. Samples were taken at 4 hours (arrow) for phase contrast microscopy (C), cell length measurements (D) and determination of curvature (E). Numbers at the bottom of micrographs in (C) refer to % xylose. Note cell debris indicative of lysis at 1% xylose. Bar = 10 μm. Cell length and percent curved cells were based on about 500 cells per condition. The sgRNA-*walA1* strain is longer than the sgRNA-neg control in all pairwise comparisons as determined by a T-test, p<0.0001.

Fig. 3. Overexpression of *walR* from a multi-copy plasmid impairs growth, alters morphology and slows autolysis in 630Δerm. A. Viability assay. Overnight cultures of 630Δerm harboring pCE691 (P_{xyl}::*walR*) or the empty vector control plasmid pBZ101 (P_{xyl} EV) were serially diluted and spotted onto TY-Thi plates with or without 1% xylose. Plates were photographed after incubation overnight. (B) Growth curve of 630Δerm/pCE691 (P_{xyl}::*walR*). Duplicate cultures were grown to an OD_{600} of 0.2, at which time one was induced with 3% xylose (green arrow). Both cultures were harvested after 3h (red arrow) for analysis by phase contrast microscopy (C) and a lysis assay (D). Bar in (C) = 10 μm. For the lysis assay, cells were suspended in buffer containing 0.01% Triton X-100 and OD_{600} was monitored over time. Error bars depict SD of 3 technical replicates. Data shown are representative of at least 3 independent experiments.

Fig. 4. Prolonged overexpression of *walR* from a single-copy chromosomal P_{xyl}::*walR* allele affects cell shape and slows lysis. (A) Growth curves. An overnight culture of strain UM626 (P$_{xyl}$::*walR* integrated at *pyrE* in 630Δerm) was subcultured 1:50 into TY with varied xylose concentrations as indicated and grown for 6 hours, then analyzed in a lysis assay (B) or by phase contrast microscopy (C). For the lysis assay, cells were suspended in buffer containing 0.01% Triton X-100 and OD$_{600}$ was monitored over time. Data are graphed as the mean and SD of 3 technical replicates, but most error bars are smaller than the symbols. Cells from cultures grown in the presence of 0-1% xylose appeared normal and are not shown, but in cultures induced with 3% xylose about 10% of the cells had irregular or bent morphologies, examples of which are shown in (C). Bar = 10 µm. Data shown are representative of at least 3 independent experiments.

Fig. 5. Comparison of transcript changes between Wal-ON and Wal-OFF conditions. (A). Heatmap showing the 79 genes whose transcript abundance changed ≥ 4-fold when *walR* was overexpressed (Wal-ON) in comparison to when the *wal* operon was silenced with CRISPRi (Wal-OFF). (B) Heatmap showing the 49 genes whose transcript abundance changed ≥ 4-fold when the *wal* operon was silenced (Wal-OFF) in comparison to when *walR* was overexpressed (Wal-ON). Green, induced. Red, repressed.

Fig. 6. Confirmation of RNA-seq results with RFP reporter fusions to select genes. Cells harboring plasmids with transcriptional fusions of the red fluorescent protein mCherryOpt to the indicated promoters were grown as per RNA-seq conditions, either Wal-ON (green) or Wal-OFF (red). Red fluorescence was measured by flow cytometry and is graphed as the mean log2-fold change from two independent experiments with two technical replicates. Error bars represent the SD of all four measurements. For comparison, the mean log2-fold change of the same genes as determined by RNA-seq is also shown. The *dltD* reporter is graphed only under Wal-OFF conditions because this fusion was induced by xylose even in the absence of P$_{xyl}$::*walR*. Genes with asterisks denote fusions that were constructed to the corresponding promoter regions from strain R20291.

Fig. 7. Perturbation of individual Wal-ON regulon genes does not replicate the Wal-ON phenotype. Overnight cultures of 630Δerm harboring overexpression plasmids were subcultured into TY-Thi to an OD_{600} of 0.03, grown to OD_{600} = 0.2 and induced with 3% xylose for 3h. Overnight cultures of 630Δerm harboring CRISPRi plasmids were subcultured into TY-Thi containing 1% xylose to an OD_{600} of 0.03 and grown to OD_{600} ~0.8. Each culture was then (A) examined by microscopy (bar 5 μm) and (B) tested in the lysis assay. Induction of *walR* is the only condition that achieved phase bright cells and slowed lysis. The plasmids used were: pBZ101 (EV), pCE691 (P_{xyl}::*walR*), pIA112 (P_{xyl}::*cd630_07380*), pIA113 (P_{xyl}::*cd630_07390*), pIA114 (P_{xyl}::*cd630_07380-07390*), pIA115 (P_{xyl}::*cd630_07390-07380*), pIA34 (sgRNA-neg), pCE744 (*sgRNA-cd630_27680-1*), and pCE745 (*sgRNA-cd630_27680-2*).

Fig. 8. Perturbation of individual Wal-OFF regulon genes does not replicate the Wal-OFF phenotype. (A) Phase contrast microscopy of strains harboring overexpression plasmids or CRISPRi plasmids after induction with xylose as described in the legend to Fig. 7. Bar = 5 µm. (B) Viability assay. Overnight cultures were serially diluted and spotted onto TY plates with or without 1% xylose. Plates were photographed after incubation overnight. CRISRPi knockdown of the *wal* operon was the only condition that resulted in curved cells, lysis or a viability defect. The plasmids used were pBZ101 (EV), pCE791 (P$_{xyl}$::*cwpV*), pIA34 (sgRNA-neg), pIA50 (sgRNA-*walA1*), and pCE738 (sgRNA-*dltD*).